Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
肾络育春丸 is a proprietary traditional Chinese medicine (TCM) formulation developed as an in-hospital preparation for the treatment of polycystic ovary syndrome (PCOS), specifically targeting subtypes such as kidney-yang deficiency with phlegm obstruction and kidney-yin deficiency with phlegm-blood stasis. It was created under the guidance of Professor Yu Jin, a renowned integrative gynecology expert, and has been used clinically since 2021. The formula is central to a TCM-based stratified treatment model for PCOS that combines herbal therapy with Western medicine, acupuncture, and psychosomatic interventions. Clinical studies have shown high ovulation (up to 90%) and pregnancy rates (up to 70%) in treated patients. The mechanism of action is based on TCM principles—tonifying the kidney, promoting blood circulation, resolving phlegm stasis, regulating menstruation—and does not correspond directly to single molecular targets or pathways recognized in Western pharmacology[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 肾络育春丸.